Aya Healthcare

ayahealthcare.com

Aya Healthcare creates exceptional experiences – for their clinicians, their corporate employees and the healthcare facilities they serve. For healthcare facilities, Aya delivers a robust suite of software and services to manage the procurement of contingent labor. Aya’s platform provides access to one of the largest sources of contract clinicians in the country which improves efficiency, increases quality and reduces costs for healthcare systems. For travel nurses, Aya delivers the best experience in the industry and allows access to the widest base of travel assignments in the United States. For more information, visit AyaHealthcare.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FOLLOWING LAB TEST, EAGLE PHARMA LOOKS TO TEST MH DRUG RYANODEX AGAINST COVID-19

BioSpace | April 16, 2020

news image

In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. Now the company hopes to launch a clinical trial testing the efficacy of the drug in patients. In the in vitro tests, Ryanodex demonstrated antiviral activity and a lack of cytotoxicity. Two days after dosing, the in vitro results showed an absence of cytopathic effects in the infected cells. This ...

Read More

Business Insights

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

news image

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More

Business Insights

CITIUS PHARMACEUTICALS, INC. SECURES $3.6 MILLION THROUGH NEW JERSEY ECONOMIC DEVELOPMENT PROGRAM

Citius Pharmaceuticals, Inc. | November 22, 2022

news image

Citius Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority. Citius expects to receive the funds by late 2022 or early ...

Read More

Business Insights

BRUKER ACQUIRES OPTIMAL COMPANIES FOR PHARMA PAT SOFTWARE AND BIOPHARMA MANUFACTURING AUTOMATION EXPERTISE AND TECHNOLOGIES

Bruker Corporation | April 06, 2022

news image

Bruker Corporation announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies. Financial details of the acquisi...

Read More
news image

FOLLOWING LAB TEST, EAGLE PHARMA LOOKS TO TEST MH DRUG RYANODEX AGAINST COVID-19

BioSpace | April 16, 2020

In a controlled laboratory test, Eagle Pharmaceuticals’ malignant hyperthermia treatment Ryanodex (dantrolene sodium) inhibited the growth of SARS-CoV-2, the virus causing the COVID-19 pandemic. Now the company hopes to launch a clinical trial testing the efficacy of the drug in patients. In the in vitro tests, Ryanodex demonstrated antiviral activity and a lack of cytotoxicity. Two days after dosing, the in vitro results showed an absence of cytopathic effects in the infected cells. This ...

Read More
news image

Business Insights

KEDRION BIOPHARMA GROWS IN NORTH AMERICA AS IT COMPLETES ACQUISITION OF PROMETIC

Kedrion Biopharma | October 19, 2021

Kedrion Biopharma, the rapidly growing international biopharmaceuticals company that produces and distributes plasma-derived treatments for rare diseases, has announced that it has completed the acquisition in North America of the Prometic life sciences business. Prometic, which has a team of 130 employees in Laval, Québec, has developed the first ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim®, , has been approved for t...

Read More
news image

Business Insights

CITIUS PHARMACEUTICALS, INC. SECURES $3.6 MILLION THROUGH NEW JERSEY ECONOMIC DEVELOPMENT PROGRAM

Citius Pharmaceuticals, Inc. | November 22, 2022

Citius Pharmaceuticals, Inc. a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that the Company has been selected to participate in New Jersey's Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss Program, and will receive $3.6 million in non-dilutive capital through the New Jersey Economic Development Authority. Citius expects to receive the funds by late 2022 or early ...

Read More
news image

Business Insights

BRUKER ACQUIRES OPTIMAL COMPANIES FOR PHARMA PAT SOFTWARE AND BIOPHARMA MANUFACTURING AUTOMATION EXPERTISE AND TECHNOLOGIES

Bruker Corporation | April 06, 2022

Bruker Corporation announced the acquisition of Optimal Industrial Automation and Technologies, a leader in pharma and biopharma process analytical technology pharma manufacturing automation and Quality Assurance (QA) software and systems integration, based in the United Kingdom. The Optimal biopharma tools acquisition strengthens Bruker as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies. Financial details of the acquisi...

Read More